Literature DB >> 29514782

The MYC oncogene is a global regulator of the immune response.

Stephanie C Casey1, Virginie Baylot1, Dean W Felsher1,2.   

Abstract

The MYC proto-oncogene is a gene product that coordinates the transcriptional regulation of a multitude of genes that are essential to cellular programs required for normal as well as neoplastic cellular growth and proliferation, including cell cycle, self-renewal, survival, cell growth, metabolism, protein and ribosomal biogenesis, and differentiation. Here, we propose that MYC regulates these programs in a manner that is coordinated with a global influence on the host immune response. MYC had been presumed to contribute to tumorigenesis through tumor cell-intrinsic influences. More recently, MYC expression in tumor cells has been shown to regulate the tumor microenvironment through effects on both innate and adaptive immune effector cells and immune regulatory cytokines. Then, MYC was shown to regulate the expression of the immune checkpoint gene products CD47 and programmed death-ligand 1. Similarly, other oncogenes, which are known to modulate MYC, have been shown to regulate immune checkpoints. Hence, MYC may generally prevent highly proliferative cells from eliciting an immune response. MYC-driven neoplastic cells have coopted this mechanism to bypass immune detection. Thus, MYC inactivation can restore the immune response against a tumor. MYC-induced tumors may be particularly sensitive to immuno-oncology therapeutic interventions.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29514782      PMCID: PMC5934797          DOI: 10.1182/blood-2017-11-742577

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  130 in total

1.  Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus.

Authors:  N C Cheng; M Beitsma; A Chan; I Op den Camp; A Westerveld; J Pronk; R Versteeg
Journal:  Oncogene       Date:  1996-10-17       Impact factor: 9.867

Review 2.  Myc family of cellular oncogenes.

Authors:  R DePinho; L Mitsock; K Hatton; P Ferrier; K Zimmerman; E Legouy; A Tesfaye; R Collum; G Yancopoulos; P Nisen
Journal:  J Cell Biochem       Date:  1987-04       Impact factor: 4.429

Review 3.  MYC oncogenes and human neoplastic disease.

Authors:  C E Nesbit; J M Tersak; E V Prochownik
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

4.  B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia.

Authors:  Weizhou Zhang; Arnon P Kater; George F Widhopf; Han-Yu Chuang; Thomas Enzler; Danelle F James; Maxim Poustovoitov; Ping-Hui Tseng; Siegfried Janz; Carl Hoh; Harvey Herschman; Michael Karin; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

Review 5.  Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch.

Authors:  Dean W Felsher
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

Review 6.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

7.  C-myc represses transiently transfected HLA class I promoter sequences not locus-specifically.

Authors:  M Griffioen; L T Peltenburg; D A van Oorschot; P I Schrier
Journal:  Immunobiology       Date:  1995-07       Impact factor: 3.144

8.  Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma.

Authors:  H Zheng; H Ying; H Yan; A C Kimmelman; D J Hiller; A-J Chen; S R Perry; G Tonon; G C Chu; Z Ding; J M Stommel; K L Dunn; R Wiedemeyer; M J You; C Brennan; Y A Wang; K L Ligon; W H Wong; L Chin; R A dePinho
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2009-01-15

9.  Suppression of MHC class I gene expression by N-myc through enhancer inactivation.

Authors:  M Lenardo; A K Rustgi; A R Schievella; R Bernards
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

10.  FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.

Authors:  Lee Pai-Scherf; Gideon M Blumenthal; Hongshan Li; Sriram Subramaniam; Pallavi S Mishra-Kalyani; Kun He; Hong Zhao; Jingyu Yu; Mark Paciga; Kirsten B Goldberg; Amy E McKee; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2017-08-23
View more
  61 in total

1.  The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth.

Authors:  Arvin M Gouw; Katherine Margulis; Natalie S Liu; Sudha J Raman; Anthony Mancuso; Georgia G Toal; Ling Tong; Adriane Mosley; Annie L Hsieh; Delaney K Sullivan; Zachary E Stine; Brian J Altman; Almut Schulze; Chi V Dang; Richard N Zare; Dean W Felsher
Journal:  Cell Metab       Date:  2019-08-22       Impact factor: 27.287

2.  Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.

Authors:  Daniel J Landsburg; Alexa Koike; Sunita D Nasta; Jakub Svoboda; Stephen J Schuster; Mariusz A Wasik; Gabriel C Caponetti
Journal:  Cancer Immunol Immunother       Date:  2020-08-28       Impact factor: 6.968

3.  The core SWI/SNF catalytic subunit Brg1 regulates nephron progenitor cell proliferation and differentiation.

Authors:  Jeannine M Basta; Ajeet P Singh; Lynn Robbins; Lisa Stout; Michelle Pherson; Michael Rauchman
Journal:  Dev Biol       Date:  2020-06-03       Impact factor: 3.582

Review 4.  Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications.

Authors:  Johann S Bergholz; Qiwei Wang; Sheheryar Kabraji; Jean J Zhao
Journal:  Clin Cancer Res       Date:  2020-06-23       Impact factor: 12.531

5.  The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?

Authors:  Wadie D Mahauad-Fernandez; Dean W Felsher
Journal:  Cancer Res       Date:  2020-07-30       Impact factor: 12.701

6.  Notch signaling defects in NK cells in patients with cancer.

Authors:  Gulnur K Zakiryanova; Elena Kustova; Nataliya T Urazalieva; Emile T Baimukhametov; Valeriy A Makarov; Gulmariya M Turaly; Galina V Shurin; Zarema M Biyasheva; Narymzhan N Nakisbekov; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2020-10-21       Impact factor: 6.968

7.  Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.

Authors:  Huiying Han; Atul D Jain; Mihai I Truica; Javier Izquierdo-Ferrer; Jonathan F Anker; Barbara Lysy; Vinay Sagar; Yi Luan; Zachary R Chalmers; Kenji Unno; Hanlin Mok; Rajita Vatapalli; Young A Yoo; Yara Rodriguez; Irawati Kandela; J Brandon Parker; Debabrata Chakravarti; Rama K Mishra; Gary E Schiltz; Sarki A Abdulkadir
Journal:  Cancer Cell       Date:  2019-10-31       Impact factor: 31.743

Review 8.  The contributions of extrachromosomal DNA elements in neoplasm progression.

Authors:  Jiawei Hong; Shusen Zheng; Donghai Jiang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

9.  Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer.

Authors:  Steven Kregel; Rohit Malik; Irfan A Asangani; Kari Wilder-Romans; Thekkelnaycke Rajendiran; Lanbo Xiao; Josh N Vo; Tanu Soni; Marcin Cieslik; Ester Fernadez-Salas; Bing Zhou; Xuhong Cao; Corey Speers; Shaomeng Wang; Arul M Chinnaiyan
Journal:  Clin Cancer Res       Date:  2019-03-27       Impact factor: 12.531

Review 10.  Obscure Involvement of MYC in Neurodegenerative Diseases and Neuronal Repair.

Authors:  Tatjana Marinkovic; Dragan Marinkovic
Journal:  Mol Neurobiol       Date:  2021-05-05       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.